Enliven Therapeutics Ownership 2024 | Who Owns Enliven Therapeutics Now?

Overview Forecast RevenueFinancials Chart

Institutional Ownership

100.00%

Insider Ownership

6.61%

Retail Ownership

-6.61%

Institutional Holders

45.00

Enliven Therapeutics Institutional Shareholders

Institutional Shareholders by % of Total Shares

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date
ORBIMED ADVISORS LLC	34.10%	3.87%	8,996,213	8,996,213	100.00%	197,017,065,000	Mar 31, 2023
5AM VENTURE MANAGEMENT, LLC	21.98%	32.47%	5,798,475	5,798,475	100.00%	126,986,603,000	Mar 31, 2023
FMR LLC	11.99%	0.01%	3,163,482	3,163,482	100.00%	69,280,255,000	Mar 31, 2023
CITADEL ADVISORS LLC	8.70%	0.01%	2,296,210	2,296,210	100.00%	50,286,999,000	Mar 31, 2023
VR ADVISER, LLC	8.39%	9.47%	2,214,142	2,214,142	100.00%	48,489,710,000	Mar 31, 2023
RA CAPITAL MANAGEMENT, L.P.	8.04%	1.05%	2,122,465	2,122,465	100.00%	46,481,984,000	Mar 31, 2023
CORMORANT ASSET MANAGEMENT, LP	7.34%	2.79%	1,936,133	1,936,133	100.00%	42,401,000	Mar 31, 2023
FAIRMOUNT FUNDS MANAGEMENT LLC	7.30%	7.25%	1,924,938	1,924,938	100.00%	42,156,142,000	Mar 31, 2023
COMMODORE CAPITAL LP	6.56%	5.77%	1,731,365	1,731,365	100.00%	37,916,894,000	Mar 31, 2023
FRAZIER LIFE SCIENCES MANAGEMENT, L.P.	3.15%	1.32%	830,983	830,983	100.00%	18,198,528,000	Mar 31, 2023
BOXER CAPITAL, LLC	2.69%	0.76%	710,644	710,644	100.00%	15,563,000	Mar 31, 2023
JANUS HENDERSON GROUP PLC	2.28%	0.01%	602,154	602,154	100.00%	13,183,336,000	Mar 31, 2023
LOGOS GLOBAL MANAGEMENT LP	1.52%	1.26%	401,229	401,229	100.00%	8,786,915,000	Mar 31, 2023
BML CAPITAL MANAGEMENT, LLC	0.80%	4.02%	212,179	212,179	100.00%	4,646,720,000	Mar 31, 2023
GROUP ONE TRADING, L.P.	0.73%	0.02%	192,700	192,700	100.00%	4,220,130,000	Mar 31, 2023
SUSQUEHANNA INTERNATIONAL GROUP, LLP	0.68%	0.00%	179,500	179,500	100.00%	3,931,050,000	Mar 31, 2023
VANGUARD GROUP INC	0.58%	0.00%	151,914	151,914	100.00%	3,326,917,000	Mar 31, 2023
RENAISSANCE TECHNOLOGIES LLC	0.27%	0.00%	70,258	70,258	100.00%	1,539,000	Mar 31, 2023
JBF CAPITAL, INC.	0.19%	0.25%	50,050	50,050	100.00%	1,096,095,000	Mar 31, 2023
MILLENNIUM MANAGEMENT LLC	0.18%	0.00%	46,874	46,874	100.00%	1,027,000	Mar 31, 2023

Enliven Therapeutics's largest institutional shareholder is ORBIMED ADVISORS LLC, holding 34.10% of the company's total share outstanding, currently valued at $197.02B. The top 10 institutional shareholders own together 117.54% of the company.

Institutional Shareholders by % of Total Assets

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date
5AM VENTURE MANAGEMENT, LLC	21.98%	32.47%	5,798,475	5,798,475	100.00%	126,986,603,000	Mar 31, 2023
VR ADVISER, LLC	8.39%	9.47%	2,214,142	2,214,142	100.00%	48,489,710,000	Mar 31, 2023
FAIRMOUNT FUNDS MANAGEMENT LLC	7.30%	7.25%	1,924,938	1,924,938	100.00%	42,156,142,000	Mar 31, 2023
COMMODORE CAPITAL LP	6.56%	5.77%	1,731,365	1,731,365	100.00%	37,916,894,000	Mar 31, 2023
BML CAPITAL MANAGEMENT, LLC	0.80%	4.02%	212,179	212,179	100.00%	4,646,720,000	Mar 31, 2023
ORBIMED ADVISORS LLC	34.10%	3.87%	8,996,213	8,996,213	100.00%	197,017,065,000	Mar 31, 2023
CORMORANT ASSET MANAGEMENT, LP	7.34%	2.79%	1,936,133	1,936,133	100.00%	42,401,000	Mar 31, 2023
FRAZIER LIFE SCIENCES MANAGEMENT, L.P.	3.15%	1.32%	830,983	830,983	100.00%	18,198,528,000	Mar 31, 2023
LOGOS GLOBAL MANAGEMENT LP	1.52%	1.26%	401,229	401,229	100.00%	8,786,915,000	Mar 31, 2023
RA CAPITAL MANAGEMENT, L.P.	8.04%	1.05%	2,122,465	2,122,465	100.00%	46,481,984,000	Mar 31, 2023
BOXER CAPITAL, LLC	2.69%	0.76%	710,644	710,644	100.00%	15,563,000	Mar 31, 2023
ACUTA CAPITAL PARTNERS, LLC	0.12%	0.50%	30,979	30,979	100.00%	678,440,000	Mar 31, 2023
JBF CAPITAL, INC.	0.19%	0.25%	50,050	50,050	100.00%	1,096,095,000	Mar 31, 2023
MIRABELLA FINANCIAL SERVICES LLP	0.04%	0.04%	11,670	11,670	100.00%	255,573,000	Mar 31, 2023
GROUP ONE TRADING, L.P.	0.73%	0.02%	192,700	192,700	100.00%	4,220,130,000	Mar 31, 2023
CITADEL ADVISORS LLC	8.70%	0.01%	2,296,210	2,296,210	100.00%	50,286,999,000	Mar 31, 2023
BRIDGEWAY CAPITAL MANAGEMENT, LLC	0.07%	0.01%	17,950	17,950	100.00%	393,105,000	Mar 31, 2023
JANUS HENDERSON GROUP PLC	2.28%	0.01%	602,154	602,154	100.00%	13,183,336,000	Mar 31, 2023
DORSEY WRIGHT & ASSOCIATES	0.00%	0.01%	1,237	1,237	100.00%	27,090,000	Mar 31, 2023
FMR LLC	11.99%	0.01%	3,163,482	3,163,482	100.00%	69,280,255,000	Mar 31, 2023

The largest Enliven Therapeutics shareholder by % of total assets is 5AM VENTURE MANAGEMENT, LLC. The company owns 5.80M shares of Enliven Therapeutics (ELVN), representing 32.47% of its total assets.

Institutional Buyers

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date
ORBIMED ADVISORS LLC	34.10%	3.87%	8,996,213	8,996,213	100.00%	197,017,065,000	Mar 31, 2023
5AM VENTURE MANAGEMENT, LLC	21.98%	32.47%	5,798,475	5,798,475	100.00%	126,986,603,000	Mar 31, 2023
FMR LLC	11.99%	0.01%	3,163,482	3,163,482	100.00%	69,280,255,000	Mar 31, 2023
CITADEL ADVISORS LLC	8.70%	0.01%	2,296,210	2,296,210	100.00%	50,286,999,000	Mar 31, 2023
VR ADVISER, LLC	8.39%	9.47%	2,214,142	2,214,142	100.00%	48,489,710,000	Mar 31, 2023
RA CAPITAL MANAGEMENT, L.P.	8.04%	1.05%	2,122,465	2,122,465	100.00%	46,481,984,000	Mar 31, 2023
CORMORANT ASSET MANAGEMENT, LP	7.34%	2.79%	1,936,133	1,936,133	100.00%	42,401,000	Mar 31, 2023
FAIRMOUNT FUNDS MANAGEMENT LLC	7.30%	7.25%	1,924,938	1,924,938	100.00%	42,156,142,000	Mar 31, 2023
COMMODORE CAPITAL LP	6.56%	5.77%	1,731,365	1,731,365	100.00%	37,916,894,000	Mar 31, 2023
FRAZIER LIFE SCIENCES MANAGEMENT, L.P.	3.15%	1.32%	830,983	830,983	100.00%	18,198,528,000	Mar 31, 2023
BOXER CAPITAL, LLC	2.69%	0.76%	710,644	710,644	100.00%	15,563,000	Mar 31, 2023
JANUS HENDERSON GROUP PLC	2.28%	0.01%	602,154	602,154	100.00%	13,183,336,000	Mar 31, 2023
LOGOS GLOBAL MANAGEMENT LP	1.52%	1.26%	401,229	401,229	100.00%	8,786,915,000	Mar 31, 2023
BML CAPITAL MANAGEMENT, LLC	0.80%	4.02%	212,179	212,179	100.00%	4,646,720,000	Mar 31, 2023
GROUP ONE TRADING, L.P.	0.73%	0.02%	192,700	192,700	100.00%	4,220,130,000	Mar 31, 2023
SUSQUEHANNA INTERNATIONAL GROUP, LLP	0.68%	0.00%	179,500	179,500	100.00%	3,931,050,000	Mar 31, 2023
VANGUARD GROUP INC	0.58%	0.00%	151,914	151,914	100.00%	3,326,917,000	Mar 31, 2023
RENAISSANCE TECHNOLOGIES LLC	0.27%	0.00%	70,258	70,258	100.00%	1,539,000	Mar 31, 2023
JBF CAPITAL, INC.	0.19%	0.25%	50,050	50,050	100.00%	1,096,095,000	Mar 31, 2023
MILLENNIUM MANAGEMENT LLC	0.18%	0.00%	46,874	46,874	100.00%	1,027,000	Mar 31, 2023

As of Mar 31 2023, Enliven Therapeutics's largest institutional buyer is ORBIMED ADVISORS LLC. The company purchased 9.00M stocks of ELVN, valued at $197.02B.

Institutional Sellers

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date
WELLS FARGO & COMPANY/MN	0.00%	-	24	24	100.00%	526,000	Mar 31, 2023
BAYSTATE WEALTH MANAGEMENT LLC	0.00%	0.00%	50	50	100.00%	1,095,000	Mar 31, 2023
JPMORGAN CHASE & CO	0.00%	-	94	94	100.00%	2,000,000	Mar 31, 2023
FEDERATED HERMES, INC.	0.00%	-	243	243	100.00%	5,322,000	Mar 31, 2023
CITADEL ADVISORS LLC	0.00%	-	250	250	100.00%	5,475,000	Mar 31, 2023
POINT72 MIDDLE EAST FZE	0.00%	0.00%	293	293	100.00%	6,417,000	Mar 31, 2023
UBS GROUP AG	0.00%	-	334	334	100.00%	7,315,000	Mar 31, 2023
ROYAL BANK OF CANADA	0.00%	-	486	486	100.00%	11,000,000	Mar 31, 2023
POINT72 ASSET MANAGEMENT, L.P.	0.00%	0.00%	746	746	100.00%	16,337,000	Mar 31, 2023
DORSEY WRIGHT & ASSOCIATES	0.00%	0.01%	1,237	1,237	100.00%	27,090,000	Mar 31, 2023
TOWER RESEARCH CAPITAL LLC (TRC)	0.01%	0.00%	1,657	1,657	100.00%	36,000	Mar 31, 2023
CITADEL ADVISORS LLC	0.01%	-	2,525	2,525	100.00%	55,298,000	Mar 31, 2023
BANK OF AMERICA CORP /DE/	0.02%	-	6,545	6,545	100.00%	143,335,000	Mar 31, 2023
BARCLAYS PLC	0.03%	0.00%	7,227	7,227	100.00%	158,000	Mar 31, 2023
CUBIST SYSTEMATIC STRATEGIES, LLC	0.03%	0.00%	8,986	8,986	100.00%	196,793,000	Mar 31, 2023
STATE STREET CORP	0.04%	-	9,424	9,424	100.00%	206,386,000	Mar 31, 2023
DIMENSIONAL FUND ADVISORS LP	0.04%	0.00%	9,915	9,915	100.00%	217,138,000	Mar 31, 2023
CITIGROUP INC	0.04%	0.00%	11,263	11,263	100.00%	246,660,000	Mar 31, 2023
MIRABELLA FINANCIAL SERVICES LLP	0.04%	0.04%	11,670	11,670	100.00%	255,573,000	Mar 31, 2023
BANK OF NEW YORK MELLON CORP	0.06%	0.00%	15,295	15,295	100.00%	334,961,000	Mar 31, 2023

As of Mar 31 2023, Enliven Therapeutics's biggest institutional seller is WELLS FARGO & COMPANY/MN. The company sold 24.00 shares of ELVN, valued at $526.00K.

Institutional New positions

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date
ORBIMED ADVISORS LLC	34.10%	3.87%	8,996,213	8,996,213	100.00%	197,017,065,000	Mar 31, 2023
5AM VENTURE MANAGEMENT, LLC	21.98%	32.47%	5,798,475	5,798,475	100.00%	126,986,603,000	Mar 31, 2023
FMR LLC	11.99%	0.01%	3,163,482	3,163,482	100.00%	69,280,255,000	Mar 31, 2023
CITADEL ADVISORS LLC	8.70%	0.01%	2,296,210	2,296,210	100.00%	50,286,999,000	Mar 31, 2023
VR ADVISER, LLC	8.39%	9.47%	2,214,142	2,214,142	100.00%	48,489,710,000	Mar 31, 2023
RA CAPITAL MANAGEMENT, L.P.	8.04%	1.05%	2,122,465	2,122,465	100.00%	46,481,984,000	Mar 31, 2023
CORMORANT ASSET MANAGEMENT, LP	7.34%	2.79%	1,936,133	1,936,133	100.00%	42,401,000	Mar 31, 2023
FAIRMOUNT FUNDS MANAGEMENT LLC	7.30%	7.25%	1,924,938	1,924,938	100.00%	42,156,142,000	Mar 31, 2023
COMMODORE CAPITAL LP	6.56%	5.77%	1,731,365	1,731,365	100.00%	37,916,894,000	Mar 31, 2023
FRAZIER LIFE SCIENCES MANAGEMENT, L.P.	3.15%	1.32%	830,983	830,983	100.00%	18,198,528,000	Mar 31, 2023
BOXER CAPITAL, LLC	2.69%	0.76%	710,644	710,644	100.00%	15,563,000	Mar 31, 2023
JANUS HENDERSON GROUP PLC	2.28%	0.01%	602,154	602,154	100.00%	13,183,336,000	Mar 31, 2023
LOGOS GLOBAL MANAGEMENT LP	1.52%	1.26%	401,229	401,229	100.00%	8,786,915,000	Mar 31, 2023
BML CAPITAL MANAGEMENT, LLC	0.80%	4.02%	212,179	212,179	100.00%	4,646,720,000	Mar 31, 2023
GROUP ONE TRADING, L.P.	0.73%	0.02%	192,700	192,700	100.00%	4,220,130,000	Mar 31, 2023
SUSQUEHANNA INTERNATIONAL GROUP, LLP	0.68%	0.00%	179,500	179,500	100.00%	3,931,050,000	Mar 31, 2023
VANGUARD GROUP INC	0.58%	0.00%	151,914	151,914	100.00%	3,326,917,000	Mar 31, 2023
RENAISSANCE TECHNOLOGIES LLC	0.27%	0.00%	70,258	70,258	100.00%	1,539,000	Mar 31, 2023
JBF CAPITAL, INC.	0.19%	0.25%	50,050	50,050	100.00%	1,096,095,000	Mar 31, 2023
MILLENNIUM MANAGEMENT LLC	0.18%	0.00%	46,874	46,874	100.00%	1,027,000	Mar 31, 2023
GOLDMAN SACHS GROUP INC	0.16%	0.00%	41,411	41,411	100.00%	906,901,000	Mar 31, 2023
GEODE CAPITAL MANAGEMENT, LLC	0.13%	0.00%	35,388	35,388	100.00%	774,997,000	Mar 31, 2023
PRELUDE CAPITAL MANAGEMENT, LLC	0.13%	0.00%	34,062	34,062	100.00%	39,989,000	Mar 31, 2023
BLACKROCK INC.	0.13%	-	33,795	33,795	100.00%	740,110,000	Mar 31, 2023
ACUTA CAPITAL PARTNERS, LLC	0.12%	0.50%	30,979	30,979	100.00%	678,440,000	Mar 31, 2023
JANE STREET GROUP, LLC	0.07%	0.00%	18,444	18,444	100.00%	403,924,000	Mar 31, 2023
BRIDGEWAY CAPITAL MANAGEMENT, LLC	0.07%	0.01%	17,950	17,950	100.00%	393,105,000	Mar 31, 2023
MORGAN STANLEY	0.07%	-	17,418	17,418	100.00%	381,454,000	Mar 31, 2023
SUSQUEHANNA INTERNATIONAL GROUP, LLP	0.07%	0.00%	17,167	17,167	100.00%	375,957,000	Mar 31, 2023
BANK OF NEW YORK MELLON CORP	0.06%	0.00%	15,295	15,295	100.00%	334,961,000	Mar 31, 2023
MIRABELLA FINANCIAL SERVICES LLP	0.04%	0.04%	11,670	11,670	100.00%	255,573,000	Mar 31, 2023
CITIGROUP INC	0.04%	0.00%	11,263	11,263	100.00%	246,660,000	Mar 31, 2023
DIMENSIONAL FUND ADVISORS LP	0.04%	0.00%	9,915	9,915	100.00%	217,138,000	Mar 31, 2023
STATE STREET CORP	0.04%	-	9,424	9,424	100.00%	206,386,000	Mar 31, 2023
CUBIST SYSTEMATIC STRATEGIES, LLC	0.03%	0.00%	8,986	8,986	100.00%	196,793,000	Mar 31, 2023
BARCLAYS PLC	0.03%	0.00%	7,227	7,227	100.00%	158,000	Mar 31, 2023
BANK OF AMERICA CORP /DE/	0.02%	-	6,545	6,545	100.00%	143,335,000	Mar 31, 2023
CITADEL ADVISORS LLC	0.01%	-	2,525	2,525	100.00%	55,298,000	Mar 31, 2023
TOWER RESEARCH CAPITAL LLC (TRC)	0.01%	0.00%	1,657	1,657	100.00%	36,000	Mar 31, 2023
DORSEY WRIGHT & ASSOCIATES	0.00%	0.01%	1,237	1,237	100.00%	27,090,000	Mar 31, 2023
POINT72 ASSET MANAGEMENT, L.P.	0.00%	0.00%	746	746	100.00%	16,337,000	Mar 31, 2023
ROYAL BANK OF CANADA	0.00%	-	486	486	100.00%	11,000,000	Mar 31, 2023
UBS GROUP AG	0.00%	-	334	334	100.00%	7,315,000	Mar 31, 2023
POINT72 MIDDLE EAST FZE	0.00%	0.00%	293	293	100.00%	6,417,000	Mar 31, 2023
CITADEL ADVISORS LLC	0.00%	-	250	250	100.00%	5,475,000	Mar 31, 2023
FEDERATED HERMES, INC.	0.00%	-	243	243	100.00%	5,322,000	Mar 31, 2023
JPMORGAN CHASE & CO	0.00%	-	94	94	100.00%	2,000,000	Mar 31, 2023
BAYSTATE WEALTH MANAGEMENT LLC	0.00%	0.00%	50	50	100.00%	1,095,000	Mar 31, 2023
WELLS FARGO & COMPANY/MN	0.00%	-	24	24	100.00%	526,000	Mar 31, 2023

Enliven Therapeutics's largest new institutional shareholder by number of shares is ORBIMED ADVISORS LLC, purchased 9.00M shares, valued at $197.02B, as of undefined.

Institutional Sold Out

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date

Enliven Therapeutics Mutual Fund Holders

Name	% Total Assets	Total Shares	Change Amount	Change %	Date
FIDELITY ADVISOR SERIES VII	0.11%	956,113	-	-	Jan 31, 2024
FIDELITY CAPITAL TRUST	0.03%	388,608	185,000	90.86%	Jan 31, 2024
VANGUARD VALLEY FORGE FUNDS	0.03%	14,831	-	-	Mar 31, 2024
FIDELITY SECURITIES FUND	0.02%	2,107,197	443,840	26.68%	Jan 31, 2024
VARIABLE INSURANCE PRODUCTS FUND IV	0.02%	60,000	-	-	Mar 31, 2024
BRIDGEWAY FUNDS INC	0.01%	16,700	-	-	Mar 28, 2024
QUANTITATIVE MASTER SERIES LLC	0.01%	42,665	-	-	Mar 31, 2024
DEUTSCHE DWS INVESTMENTS VIT FUNDS	0.01%	3,610	-	-	Mar 31, 2024
Nushares ETF Trust	0.00%	22,053	-625	-2.76%	Jan 31, 2024
TIAA SEPARATE ACCOUNT VA 1	0.00%	619	-	-	Mar 31, 2024
VANGUARD INDEX FUNDS	0.00%	957,309	-360,131	-27.34%	Mar 31, 2024
Fidelity Central Investment Portfolios LLC	0.00%	100,000	-	-	Mar 31, 2024
SCHWAB CAPITAL TRUST	0.00%	62,462	-	-	Jan 31, 2024
VARIABLE INSURANCE PRODUCTS FUND	0.00%	28,000	-	-	Mar 31, 2024
Calvert Variable Products, Inc.	0.00%	1,928	-	-	Mar 31, 2024
FIDELITY COVINGTON TRUST	0.00%	9,559	-150	-1.54%	Jan 31, 2024
ETF Series Solutions	0.00%	10,245	1,641	19.07%	Feb 29, 2024
VANGUARD INSTITUTIONAL INDEX FUNDS	0.00%	13,834	-997	-6.72%	Mar 31, 2024
AdvisorShares Trust	0.00%	1,375	-	-	Mar 28, 2024
Voya VARIABLE PORTFOLIOS INC	0.00%	8,358	-1,310	-13.55%	Mar 31, 2024
Global X Funds	0.00%	11,276	-	-	Jan 31, 2024
STATE STREET VARIABLE INSURANCE SERIES FUNDS INC	0.00%	1,129	-	-	Mar 31, 2024
TIAA-CREF LIFE FUNDS	0.00%	352	-	-	Mar 31, 2024
STATE STREET INSTITUTIONAL INVESTMENT TRUST	0.00%	8,400	1,000	13.51%	Mar 31, 2024
NORTHERN FUNDS	0.00%	18,476	-800	-4.15%	Mar 28, 2024
T. Rowe Price Index Trust, Inc.	0.00%	1,501	252	20.18%	Mar 31, 2024
iSHARES TRUST	0.00%	1,004,051	-34,726	-3.34%	Mar 31, 2024
RYDEX SERIES FUNDS	0.00%	213	-	-	Dec 31, 2023
EQ ADVISORS TRUST	0.00%	56,203	-1,148	-2.00%	Mar 31, 2024
Invesco Exchange-Traded Self-Indexed Fund Trust	0.00%	9,137	-	-	Feb 29, 2024
PENN SERIES FUNDS INC	0.00%	900	-	-	Mar 28, 2024
NATIONWIDE MUTUAL FUNDS	0.00%	3,858	-20	-0.52%	Jan 31, 2024
RYDEX DYNAMIC FUNDS	0.00%	106	-	-	Dec 31, 2023
NATIONWIDE VARIABLE INSURANCE TRUST	0.00%	3,400	-	-	Mar 31, 2024
AMERICAN CENTURY ETF TRUST	0.00%	2,741	2,741	-	Feb 29, 2024
J.P. Morgan Exchange-Traded Fund Trust	0.00%	10,415	-	-	Jan 31, 2024
Goldman Sachs ETF Trust	0.00%	1,687	-1,436	-45.98%	Feb 29, 2024
TIAA-CREF FUNDS	0.00%	51,583	-	-	Jan 31, 2024
ProFunds	0.00%	181	-15	-7.65%	Mar 31, 2024
RYDEX VARIABLE TRUST	0.00%	14	-	-	Dec 31, 2023
USAA MUTUAL FUNDS TRUST	0.00%	2,598	201	8.39%	Jan 31, 2024
COLLEGE RETIREMENT EQUITIES FUND	0.00%	11,571	-	-	Mar 31, 2024
Brighthouse Funds Trust II	0.00%	7,852	-	-	Mar 31, 2024
ALLSPRING MASTER TRUST	0.00%	566	-	-	Feb 29, 2024
LINCOLN VARIABLE INSURANCE PRODUCTS TRUST	0.00%	19,500	-	-	Mar 31, 2024
SUNAMERICA SERIES TRUST	0.00%	2,645	-10	-0.38%	Jan 31, 2024
JOHN HANCOCK VARIABLE INSURANCE TRUST	0.00%	9,761	-285	-2.84%	Mar 31, 2024
FIDELITY SALEM STREET TRUST	0.00%	17,308	-382	-2.16%	Mar 31, 2024
Dimensional ETF Trust	0.00%	1,470	-	-	Jan 31, 2024
PACIFIC SELECT FUND	0.00%	9,074	-234	-2.51%	Mar 31, 2024
Bridge Builder Trust	0.00%	9,283	-	-	Mar 31, 2024
SPDR INDEX SHARES FUNDS	0.00%	342	15	4.59%	Mar 31, 2024
DFA INVESTMENT DIMENSIONS GROUP INC	0.00%	1,526	-	-	Jan 31, 2024
BlackRock Variable Series Funds, Inc.	0.00%	2,837	-	-	Mar 31, 2024
BLACKROCK FUNDS	0.00%	3,584	-	-	Jan 31, 2024
PRINCIPAL FUNDS, INC.	0.00%	2,991	-505	-14.45%	Jan 31, 2024
FIDELITY SUMMER STREET TRUST	0.00%	77	-	-	Jan 31, 2024

Enliven Therapeutics's largest mutual fund holder by % of total assets is "FIDELITY ADVISOR SERIES VII", owning 956.11K shares, compromising 0.11% of its total assets.

Enliven Therapeutics Institutional Ownership Trends

Institutional Holdings Trend

Date	Holdings	Change %
31 Mar, 23	45	-

As of 31 Mar 23, 45 institutions are holding Enliven Therapeutics's shares, representing an increase of 0.00% compared to the previous quarter.

Shares Outstanding Trend

Date	Shares Outstanding	Change %
31 Mar, 23	33,591,811	-

Enliven Therapeutics (ELVN) has 33.59M shares outstanding as of 31 Mar 23, up 0.00% compared to the previous quarter.

Institutional Ownership Trend

Date	Ownership %	Change %
31 Mar, 23	100.00%	-

Institutional Increased Positions Trend

Date	Increased Positions	Change %
31 Mar, 23	-	-

Institutional Reduced Positions Trend

Date	Reduced Positions	Change %
31 Mar, 23	-	-

All Institutional Ownership Trend Data

Date	Holdings	Change %	Shares Outstanding	Change %	Ownership %	Change %	Increased Positions	Change %	Reduced Positions	Change %
31 Mar, 23	45	-	33,591,811	-	100.00%	-	-	-	-	-

Enliven Therapeutics Insider Shareholders Trades

Open Market Insider Trades

Date	Name	Relation	Role	Transaction	Buy/Sell	Shares	Price	Value	Shares Held
Aug 02, 2024	Lyssikatos Joseph P	officer	CHIEF SCIENTIFIC OFFICER	S-Sale	Sell	3,099	$27.56	$85.40K	1,089,936
Aug 02, 2024	Kintz Samuel	director, officer	PRESIDENT AND CEO	S-Sale	Sell	2,270	$27.56	$62.56K	1,061,255
Aug 02, 2024	Hohl Benjamin	officer	CHIEF FINANCIAL OFFICER	S-Sale	Sell	991	$27.53	$27.28K	-
Aug 02, 2024	Heyman Richard A.	director	-	S-Sale	Sell	1,702	$27.51	$46.82K	131,643
Aug 02, 2024	Heyman Richard A.	director	-	S-Sale	Sell	649	$27.50	$17.85K	27,918
Jul 31, 2024	Lyssikatos Joseph P	officer	CHIEF SCIENTIFIC OFFICER	S-Sale	Sell	11,797	$26.69	$314.81K	1,093,238
Jul 31, 2024	Lyssikatos Joseph P	officer	CHIEF SCIENTIFIC OFFICER	S-Sale	Sell	203	$27.43	$5.57K	1,093,035
Jul 31, 2024	Hohl Benjamin	officer	CHIEF FINANCIAL OFFICER	S-Sale	Sell	5,189	$26.67	$138.38K	61
Jul 31, 2024	Hohl Benjamin	officer	CHIEF FINANCIAL OFFICER	S-Sale	Sell	61	$27.44	$1.67K	-
Jul 29, 2024	Kintz Samuel	director, officer	PRESIDENT AND CEO	S-Sale	Sell	3,793	$24.53	$93.04K	1,071,732
Jul 29, 2024	Kintz Samuel	director, officer	PRESIDENT AND CEO	S-Sale	Sell	8,164	$25.10	$204.92K	1,063,568
Jul 29, 2024	Kintz Samuel	director, officer	PRESIDENT AND CEO	S-Sale	Sell	43	$25.83	$1.11K	1,063,525
Jul 17, 2024	Heyman Richard A.	director	-	S-Sale	Sell	1,270	$24.80	$31.50K	133,345
Jul 16, 2024	Patel Anish	officer	CHIEF OPERATING OFFICER	S-Sale	Sell	17,475	$25.07	$438.09K	376,552
Jul 16, 2024	Patel Anish	officer	CHIEF OPERATING OFFICER	S-Sale	Sell	30,978	$25.05	$776.04K	345,574
Jul 16, 2024	Patel Anish	officer	CHIEF OPERATING OFFICER	S-Sale	Sell	1,547	$25.01	$38.69K	344,027

Open Market Insider Buys

Date	Name	Relation	Role	Transaction	Buy/Sell	Shares	Price	Value	Shares Held	Source

Insider Sells

Date	Name	Relation	Role	Transaction	Buy/Sell	Shares	Price	Value	Shares Held
Aug 02, 2024	Lyssikatos Joseph P	officer	CHIEF SCIENTIFIC OFFICER	S-Sale	Sell	3,099	$27.56	$85.40K	1,089,936
Aug 02, 2024	Kintz Samuel	director, officer	PRESIDENT AND CEO	S-Sale	Sell	2,270	$27.56	$62.56K	1,061,255
Aug 02, 2024	Hohl Benjamin	officer	CHIEF FINANCIAL OFFICER	M-Exempt	Sell	991	$2.48	$2.46K	203,379
Aug 02, 2024	Hohl Benjamin	officer	CHIEF FINANCIAL OFFICER	S-Sale	Sell	991	$27.53	$27.28K	-
Aug 02, 2024	Heyman Richard A.	director	-	S-Sale	Sell	1,702	$27.51	$46.82K	131,643
Aug 02, 2024	Heyman Richard A.	director	-	S-Sale	Sell	649	$27.50	$17.85K	27,918
Jul 31, 2024	Lyssikatos Joseph P	officer	CHIEF SCIENTIFIC OFFICER	S-Sale	Sell	11,797	$26.69	$314.81K	1,093,238
Jul 31, 2024	Lyssikatos Joseph P	officer	CHIEF SCIENTIFIC OFFICER	S-Sale	Sell	203	$27.43	$5.57K	1,093,035
Jul 31, 2024	Hohl Benjamin	officer	CHIEF FINANCIAL OFFICER	M-Exempt	Sell	5,250	$2.48	$13.02K	204,370
Jul 31, 2024	Hohl Benjamin	officer	CHIEF FINANCIAL OFFICER	S-Sale	Sell	5,189	$26.67	$138.38K	61
Jul 31, 2024	Hohl Benjamin	officer	CHIEF FINANCIAL OFFICER	S-Sale	Sell	61	$27.44	$1.67K	-
Jul 29, 2024	Kintz Samuel	director, officer	PRESIDENT AND CEO	S-Sale	Sell	3,793	$24.53	$93.04K	1,071,732
Jul 29, 2024	Kintz Samuel	director, officer	PRESIDENT AND CEO	S-Sale	Sell	8,164	$25.10	$204.92K	1,063,568
Jul 29, 2024	Kintz Samuel	director, officer	PRESIDENT AND CEO	S-Sale	Sell	43	$25.83	$1.11K	1,063,525
Jul 17, 2024	Heyman Richard A.	director	-	S-Sale	Sell	1,270	$24.80	$31.50K	133,345
Jul 16, 2024	Patel Anish	officer	CHIEF OPERATING OFFICER	S-Sale	Sell	17,475	$25.07	$438.09K	376,552
Jul 16, 2024	Patel Anish	officer	CHIEF OPERATING OFFICER	S-Sale	Sell	30,978	$25.05	$776.04K	345,574
Jul 16, 2024	Patel Anish	officer	CHIEF OPERATING OFFICER	S-Sale	Sell	1,547	$25.01	$38.69K	344,027

All Insider Owners Trades

Date	Name	Relation	Role	Transaction	Buy/Sell	Shares	Price	Value	Shares Held
Aug 02, 2024	Lyssikatos Joseph P	officer	CHIEF SCIENTIFIC OFFICER	S-Sale	Sell	3,099	$27.56	$85.40K	1,089,936
Aug 02, 2024	Kintz Samuel	director, officer	PRESIDENT AND CEO	S-Sale	Sell	2,270	$27.56	$62.56K	1,061,255
Aug 02, 2024	Hohl Benjamin	officer	CHIEF FINANCIAL OFFICER	M-Exempt	Sell	991	$2.48	$2.46K	203,379
Aug 02, 2024	Hohl Benjamin	officer	CHIEF FINANCIAL OFFICER	M-Exempt	Buy	991	$2.48	$2.46K	991
Aug 02, 2024	Hohl Benjamin	officer	CHIEF FINANCIAL OFFICER	S-Sale	Sell	991	$27.53	$27.28K	-
Aug 02, 2024	Heyman Richard A.	director	-	S-Sale	Sell	1,702	$27.51	$46.82K	131,643
Aug 02, 2024	Heyman Richard A.	director	-	S-Sale	Sell	649	$27.50	$17.85K	27,918
Jul 31, 2024	Lyssikatos Joseph P	officer	CHIEF SCIENTIFIC OFFICER	S-Sale	Sell	11,797	$26.69	$314.81K	1,093,238
Jul 31, 2024	Lyssikatos Joseph P	officer	CHIEF SCIENTIFIC OFFICER	S-Sale	Sell	203	$27.43	$5.57K	1,093,035
Jul 31, 2024	Hohl Benjamin	officer	CHIEF FINANCIAL OFFICER	M-Exempt	Sell	5,250	$2.48	$13.02K	204,370
Jul 31, 2024	Hohl Benjamin	officer	CHIEF FINANCIAL OFFICER	M-Exempt	Buy	5,250	$2.48	$13.02K	5,250
Jul 31, 2024	Hohl Benjamin	officer	CHIEF FINANCIAL OFFICER	S-Sale	Sell	5,189	$26.67	$138.38K	61
Jul 31, 2024	Hohl Benjamin	officer	CHIEF FINANCIAL OFFICER	S-Sale	Sell	61	$27.44	$1.67K	-
Jul 29, 2024	Kintz Samuel	director, officer	PRESIDENT AND CEO	S-Sale	Sell	3,793	$24.53	$93.04K	1,071,732
Jul 29, 2024	Kintz Samuel	director, officer	PRESIDENT AND CEO	S-Sale	Sell	8,164	$25.10	$204.92K	1,063,568
Jul 29, 2024	Kintz Samuel	director, officer	PRESIDENT AND CEO	S-Sale	Sell	43	$25.83	$1.11K	1,063,525
Jul 17, 2024	Heyman Richard A.	director	-	S-Sale	Sell	1,270	$24.80	$31.50K	133,345
Jul 16, 2024	Patel Anish	officer	CHIEF OPERATING OFFICER	S-Sale	Sell	17,475	$25.07	$438.09K	376,552
Jul 16, 2024	Patel Anish	officer	CHIEF OPERATING OFFICER	S-Sale	Sell	30,978	$25.05	$776.04K	345,574
Jul 16, 2024	Patel Anish	officer	CHIEF OPERATING OFFICER	S-Sale	Sell	1,547	$25.01	$38.69K	344,027

The last insider sell of Enliven Therapeutics's stock was made by Lyssikatos Joseph P on Aug 02 2024, selling 3,099 shares at $27.56 per share (valued at $85.40K).

Enliven Therapeutics Insider Ownership Trends

All Insider Trades Trend

Date	Buy	Sell	Buy/Sell Ratio
Q3 2024	3	21	14.29%
Q2 2024	25	75	33.33%
Q1 2024	25	30	83.33%
Q3 2023	-	4	-
Q1 2023	1	-	-
Q2 2003	1	-	-

3 total buy trades, and 21 total sell trades (buy/sell ratio of 0.14%) were made by Enliven Therapeutics's insiders, as of Q3 2024.

Open Market Insider Trades Trend

Date	Buy	Sell	Buy/Sell Ratio
Q3 2024	-	18	-
Q2 2024	-	49	-
Q1 2024	-	22	-
Q3 2023	-	4	-
Q1 2023	-	-	-
Q2 2003	-	-	-

As of Q3 2024, Insider owners conducted 0 open market buy trades and 18 open market sell trades of Enliven Therapeutics's stocks.

Enliven Therapeutics Peer Ownership

Ticker	Company
PMVP	PMV Pharmaceuticals, Inc.
GOSS	Gossamer Bio, Inc.
CGEM	Cullinan Oncology, Inc.
AVTE	Aerovate Therapeutics, Inc.
INBX	Inhibrx Biosciences, Inc.
REPL	Replimune Group, Inc.
KRON	Kronos Bio, Inc.
MLTX	MoonLake Immunotherapeutics
GPCR	Structure Therapeutics Inc.
IMRX	Immuneering Corporation
LYRA	Lyra Therapeutics, Inc.
CELC	Celcuity Inc.
MACK	Merrimack Pharmaceuticals, Inc.
NVCT	Nuvectis Pharma, Inc.
CMPX	Compass Therapeutics, Inc.
ELYM	Eliem Therapeutics, Inc.

ELVN Ownership FAQ

Who Owns Enliven Therapeutics?

Enliven Therapeutics is owned by institutional shareholders (100.00%), insiders (6.61%), and public (-6.61%). The largest institutional shareholder of Enliven Therapeutics is ORBIMED ADVISORS LLC (34.10% of total shares) and the top mutual fund owner is FIDELITY ADVISOR SERIES VII (0.11% of total shares).

Who are the major institutional shareholders of Enliven Therapeutics?

Enliven Therapeutics's major institutional shareholders are ORBIMED ADVISORS LLC, 5AM VENTURE MANAGEMENT, LLC, FMR LLC, CITADEL ADVISORS LLC, and VR ADVISER, LLC. The top five shareholders own together 85.15% of the company's share outstanding.

How many Enliven Therapeutics shareholders are there?

As of Mar 2023, there are 45 institutional shareholders of Enliven Therapeutics.

What percentage of Enliven Therapeutics is owned by ORBIMED ADVISORS LLC?

ORBIMED ADVISORS LLC owns 9M shares of Enliven Therapeutics, representing 34.10% of the company's total shares outstanding, valued at $197.02B (as of Mar 2023).

What percentage of Enliven Therapeutics is owned by 5AM VENTURE MANAGEMENT, LLC?

As of Mar 2023, 5AM VENTURE MANAGEMENT, LLC holds 5.8M shares of Enliven Therapeutics (ELVN), compromising 21.98% of the company, valued at $126.99B.

What percentage of Enliven Therapeutics is owned by FMR LLC?

FMR LLC is the third largest holder of Enliven Therapeutics. The company owns 3.16M of the company's shares outstanding (worth $69.28B).